Dynegy Inc. (NYSE:DYN) shares increased 3.24% in last trading session and ended the day at $13.71. DYN Gross Margin is 47.10% and its has a return on assets of 0.20%. Dynegy Inc. (NYSE:DYN) quarterly performance is 12.38%.
Dynegy Inc. (NYSE:DYN) said that, its request to close its doors was approved and the facility will most likely shut down effective June 1.
On 24 March, Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) shares increased 2.23% and was closed at $1.83. ARNA EPS growth in last 5 year was 17.00%. Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) year to date (YTD) performance is -3.68%.
Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) is expected to announce first quarter financial results after market close (confirmed) on 05/09/2016.
The Walt Disney Company (NYSE:DIS) shares increased 0.40% in last trading session and ended the day at $97.22. DIS Gross Margin is 46.00% and its has a return on assets of 10.30%. The Walt Disney Company (NYSE:DIS) quarterly performance is -8.92%.
The Walt Disney Company (NYSE:DIS) has debuted a special package designed for preschool families. Beginning May 30 – Aug. 25, 2016, guests can enjoy a three-night, two-day vacation package with theme park tickets starting at $1,021 for a family of three at one of Disney’s All-Star Resorts.
KeyCorp. (NYSE:KEY) shares moved down -0.62% in last trading session and ended the day at $11.19. KEY has a return on assets of 0.90%. KeyCorp. (NYSE:KEY) quarterly performance is -13.31%.
On 23 March, KeyCorp. (NYSE:KEY) said that, its plans are part of an agreement with the National Community Reinvestment Coalition, which includes more than 600 community organizations that promote access to basic banking services, affordable housing and job development for working families.
Anthera Pharmaceuticals, Inc. (NASDAQ:ANTH) caters to the Healthcare space. Its weekly performance is -5.46%. On the last day of trading company shares ended up at $3.46. Anthera Pharmaceuticals, Inc. (NASDAQ:ANTH) distance from 50-day simple moving average (SMA50) is 9.80%.
Zacks Investment Research upgraded shares of Anthera Pharmaceuticals Inc (NASDAQ:ANTH) from a hold rating to a buy rating in a research report released on Friday, MarketBeat.Com reports. Zacks Investment Research currently has $4.75 price target on the biopharmaceutical company’s stock.
Leave a Reply